BAY 949392

Drug Profile

BAY 949392

Alternative Names: 18F-FSPG; BAY94-9392; FSPG

Latest Information Update: 19 Sep 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Developer Bayer HealthCare Pharmaceuticals; National Cancer Institute (USA); Piramal Enterprises; Stanford University
  • Class Radiopharmaceutical diagnostics
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cancer
  • Phase I Brain cancer
  • No development reported Inflammation

Most Recent Events

  • 10 Apr 2017 Stanford University plans a phase II trial for Inflammation (Diagnosis) (NCT03103490)
  • 31 Aug 2016 Piramal Imaging terminates a phase I trial in Brain cancer in USA (NCT02370563)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer(Diagnosis) in Germany (IV, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top